SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant momentum as the community eagerly anticipates Phase 3 results for its promising AML drug, GPS, with many anticipating a potential buyout fueled by conviction in the science and high short interest, leading to strong expectations of a major upward repricing. Investors are actively discussing the drug's "functional cure" potential and celebrating the stock's multi-year highs.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is actively discussed after securing major partnerships with TELUS and Axian Telecom, bolstering its impressive contracted revenue and liquidity, with the community celebrating its shift from a concept to a revenue-generating leader in direct-to-device satellite connectivity. Investors are focused on accelerated satellite deployment and the potential for substantial future revenue and high margins, positioning the stock as a strong performer despite broader market weakness.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid high anticipation for its upcoming earnings, as the community fiercely debates its valuation and strategic position in the evolving Agentic AI landscape. Investors are polarized between those highlighting its strong balance sheet, institutional ownership, and role as an AI orchestration platform, and those concerned about competition and recent price weakness, fueling speculation of a potential short squeeze.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as community discussion revolves around the escalating conflict with Iran, widely seen as a potential distraction from 'Epstein files' revelations, generating strong investor concern about geopolitical instability and its impact on energy markets.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending following a notable price breakout past resistance, sparking intense debate as bulls celebrate liquidated shorts and bears anticipate a bull trap. Community discussion is focused on BTC's potential as a safe haven amid geopolitical tensions, alongside former President Trump's strong advocacy for crypto-friendly legislation.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending following its Q4 earnings beat, which was quickly overshadowed by conservative forward guidance for FY27. This has created a sharp divide in the community, with bulls highlighting undervaluation and AI growth opportunities including a $400M buyback, while bears cite slowing growth and broader AI competition pressures on the SaaS sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as reports indicate major automakers are exiting its EU carbon credit pool, potentially impacting a revenue stream, while Elon Musk's ambitious push into AI and humanoid robotics sparks intense community debate over the company's future direction amidst broader market volatility.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending sharply upward after its robust Q4 earnings reported significant growth in USDC circulation and profitability, fueling a massive short squeeze. The community is buzzing about its foundational role in AI agentic commerce and its potential to benefit from both favorable stablecoin regulation and persistent interest rate levels.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital (APLD) is trending after a proposed $2.15 billion non-dilutive senior secured notes offering revealed Oracle as the tenant for its Polaris Forge 2 campus. The community is actively discussing this growth funding and Oracle's confirmation, with many anticipating a new hyperscaler lease announcement to further solidify APLD's position in the expanding AI infrastructure market.

Wix.com Ltd. engages in providing a web development platform for creators, delivering its solutions through a Software-as-a-Service model. Its products include website templates, website builder, website design, Wix features, app market, web hosting, domain names, website accessibility, mobile app builder, and AI website builder. The company was founded by Avishai Abrahami, Nadav Abrahami, Nir Zohar, and Giora Kaplan on October 5, 2006 and is headquartered in Tel Aviv, Israel.

Wix.com Ltd

Wix is trending after a mixed earnings report that saw an EPS beat offset by a revenue miss, fueling community debate. Investors are actively discussing the company's substantial share repurchase program, robust free cash flow, and strategic AI integrations like Base44 and Harmony as potential catalysts, while also weighing concerns about broader AI disruption in the web development space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases  DelveInsight

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight Chronic Kidney Disease...

Amgen EVP Sold $20.77M In Company Stock

Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan

SNY wins Japan orphan drug tag for Waylirz in IgG4-RD and adds regulatory perks as the BTK inhibitor advances in late-stage studies.

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Fisher Asset Management LLC Acquires 375,463 Shares of Amgen Inc. $AMGN

Fisher Asset Management LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 91.6% in the third quarter, according to the company in its most recent disclosure with the...

Amgen (NASDAQ:AMGN) Sets New 1-Year High - Should You Buy?

Amgen (NASDAQ:AMGN) Sets New 52-Week High - Should You Buy...

Amgen Touts Broad Portfolio Momentum, MariTide Milestones and Repatha Access Push at TD Cowen Conf

Amgen (NASDAQ:AMGN) executives highlighted broad-based commercial momentum, a focus on long-term growth drivers, and several upcoming pipeline milestones during a fireside chat at the 46th Annual TD...

<ul class="summary-bullets"><li>Founder and executive chairman Patrick Soon-Shiong called a rare public speech his “prelude” to Tuesday’s earnings update.</li><li>The company is set to report FY25 results on Tuesday, with estimates pointing to revenue of $113.3 million versus $14.8 million in 2024 and narrowing losses.</li><li>Anktiva generated $113 million in net product revenue in 2025, up 700% year over year, while Q4 revenue climbed 431% to $38.3 million.</li></ul>Shares of ImmunityBio, Inc. (IBRX) extended their three-day rally on Monday, with founder and executive chairman Patrick Soon-Shiong adding fuel to the stock by calling a rare public speech a “prelude” to its earnings update due Tuesday.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> rose nearly 7% on Monday to end at $10.44 and slipped slightly in extended trading.&nbsp;<h2 class="st-heading-2">IL-15 Spotlighted As Anktiva’s Core Engine</h2>Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2028658871623905656">said on X</a> that his remarks from last week, delivered at an event marking the 55th anniversary of President Richard Nixon’s “war on cancer,” were a “prelude” to ImmunityBio’s upcoming earnings.He criticized decades-old cancer treatment strategies, arguing that many chemotherapy drugs were developed without fully accounting for the immune system. He said high-dose chemo and radiation can significantly reduce vital immune cells like NK cells and T cells, creating a condition known as lymphopenia.&nbsp;He called the absolute lymphocyte count (ALC), a blood-test metric, “hidden in plain sight,” saying immune depletion has been underappreciated despite its measurability.Soon-Shiong also criticized major cancer drugs, citing Taxol, which is marketed by Bristol Myers, and Amgen’s Neupogen. He argued that these approaches reflected an industry-wide strategy of enabling more intensive chemotherapy and managing its side effects, rather than addressing underlying immune suppression.Against that backdrop, he spotlighted IL-15 as the biological engine behind Anktiva, positioning it as an immune amplifier rather than a traditional therapy. He contrasted older IL-2 approaches with IL-15 biology, saying IL-15 expands natural killer cells and memory cells without boosting immunosuppressive cells.&nbsp;<h2 class="st-heading-2">IBRX 2025 Results Preview</h2>ImmunityBio is set to report full-year&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-eyes-green-open-ahead-of-earnings-what-happened-with-anktiva-over-the-weekend/cZddUNHRIcl">2025 earnings</a> on Tuesday, with expectations for sharply higher revenue and narrowing losses as Anktiva's commercialization scales.Fiscal AI estimates 2025 revenue of $113.29 million, up from $14.75 million in 2024, with loss per share improving to $0.38 from $0.59. The company has indicated $113 million in net product revenue for Anktiva in 2025, up 700% year over year, while fourth-quarter revenue rose 431% to $38.3 million, topping estimates. Full-year net loss attributable to common shareholders improved to $351.4 million from $413.6 million in 2024.<h2 class="st-heading-2">Regulatory Wins Bolster Anktiva Outlook</h2>Soon-Shiong has recently amplified Anktiva’s IL-15 mechanism in national media appearances and highlighted combination approaches with checkpoint inhibitors such as Merck’s Keytruda.&nbsp;ImmunityBio recently completed enrollment ahead of schedule in its Phase 2 Quilt 2.005 trial evaluating Anktiva plus BCG in early-stage bladder cancer, citing improved cancer-free rates compared with standard BCG alone. A biologics license application for the regimen is expected by the fourth quarter of 2026.Anktiva is already approved in combination with BCG for bladder cancer in the U.S. and has received authorizations in the UK, Europe, and Saudi Arabia, where regulators also granted accelerated approval for use with a checkpoint inhibitor in metastatic non-small cell lung cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX was ‘bullish’ amid a 185% jump in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_09ff793a38.webp" alt="ibrx ss.png" width="967" height="144"><figcaption>IBRX sentiment and message volume as of March 3 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/PureLand/message/646395463">said</a> that, “If [broader Saudi] approval comes through, the stock could jump toward $20 quickly, and a squeeze could drive it over $100.”<stembedurl>https://stocktwits.com/PureLand/message/646395463</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/MrStockxy/message/646392467">said</a>, “Will be go[ing to] $11 tomorrow. Let’s bet.”<stembedurl>https://stocktwits.com/MrStockxy/message/646392467</stembedurl>IBRX stock has surged over 400% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

Equity

Promising Medical Stocks To Consider - March 2nd

Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, AbbVie, Rapt Therapeutics, Novo Nordisk A/S, and Amgen are the seven Medical stocks to watch today, according to MarketBeat's stock...

Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus

Contineum Therapeutics surged 27% after a Zacks Rank upgrade, spotlighting how Zacks' strategies are beating a volatile market.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGN
AMGEN Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AMGN News

AMGNAMGEN Inc.